|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
MT Aye and JV Dunne
The finding of elevated intracellular levels of adenosine deaminase (ADA)
in some patients with acute lymphoblastic leukemia has led to attempts to
control this disease with the adenosine deaminase inhibitor
2'-deoxycoformycin (dCF). Because of clinical reports indicating its
relative freedom from myelotoxicity, we have tested the effects of this
drug on erythroid, granulocytic, and T-lymphocyte colony formation by
normal marrow and peripheral blood cells. While clinically the drug has
been found to be active at serum concentrations of approximately 10 microM,
we have tested it at concentrations up to and including 1 mM. It was found
that both erythroid and granulocytic colony growth was completely
unaffected by 1 mM dCF, a concentration at least 2 magnitudes higher than
that necessary to totally ablate intracellular ADA levels. T-lymphocyte
colony growth was unaffected by 100 microM dCF, but at 1 mM some inhibition
was observed. These findings therefore indicate that dCF, while able to
cause leukemic cell lysis in vivo, has no inhibitory effect on the
proliferative capacity of normal hematopoietic cells.
This article has been cited by other articles:
| |||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 1981 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
